At Aro, we're developing a patented platform technology called Centyrins that are uniquely positioned to achieve precise targeting of diverse therapeutic payloads to specific cells of interest. Centyrins are small protein domains based on the fibronectin domains of human Tenascin C that combine the affinity and specificity properties of antibodies with the stability and tissue penetration properties of small molecules. Our efforts are focused on discovering and developing Centyrin-oligonucleotide conjugate therapies that are meant to address one of the greatest challenges facing oligonucleotide-based medicines today: targeted delivery of oligonucleotides to extra-hepatic tissues. Led by an experienced and extraordinary team, Aro is backed by an exceptional syndicate that supports our commitment to advancing drug candidates with the potential to improve patient's lives and to building an ideal environment for scientific and leadership growth.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Career Level
Entry Level
Industry
Professional, Scientific, and Technical Services
Number of Employees
11-50 employees